Ticker
ACLX

Price
32.13
Stock movement down
-0.57 (-1.74%)
Company name
Arcellx Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Markedsværdi
1.41B
Ent værdi
1.45B
Pris/omsætning
-
Pris/bog
5.96
Udbytte afkast
-
Udbyttevækst
-
Vekst år
-
FCF-udbetaling
-
Efterfølgende P/E
-
Fremtidig P/E
-
PEG
-
EPS-vekst
-
1 års afkast
114.20%
3 års afkast
-
5 års afkast
-
10 års afkast
-
Senest opdateret: 2023-02-06

UDBYTTE

ACLX betaler ikke udbytte

VÆRDIANSÆTTELSE

Værdiansættelsesforhold

Loading...
Værdiansættelsesforhold-data
Efterfølgende P/E-
Pris til OCF-
Pris til FCF-
Pris til EBITDA-
EV i forhold til EBITDA-

Værdiansættelse (salg/bogført værdi)

Loading...
Værdiansættelse (salg/bogført værdi)-data
Pris til omsætning-
Pris til egenkapital5.96
EV i forhold til salg-

ØKONOMI

Pr. aktie

Loading...
Data pr. aktie
Aktuelt antal aktier43.85M
EPS (TTM)-5.07
FCF pr. aktie (TTM)-3.02

Resultatopgørelse

Loading...
Resultatopgørelse-data
Omsætning (TTM)0.00
Bruttofortjeneste (TTM)0.00
Driftsindkomst (TTM)-179.62M
Nettoindkomst (TTM)-222.32M
EPS (TTM)-5.07
EPS (1 år frem)-2.36

Marginer

Loading...
Marginer-data
Bruttomargin (TTM)-
Driftsmargin (TTM)-
Fortjenstmargin (TTM)-

Balance

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Balancedata
Kontanter56.76M
Nettotilgodehavender0.00
Omsætningsaktiver i alt290.31M
Goodwill0.00
Immaterielle aktiver0.00
Ejendomme, anlæg og udstyr0.00
Sum aktiver337.33M
Kreditor2.96M
Kortfristet/nuværende langsigtet gæld86.87M
Summen af kortfristede forpligtelser44.78M
Sum gæld101.04M
Aktionærernes egenkapital236.28M
Materielle nettoaktiver236.28M

Likviditet

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Kontantstrøm-data
Likviditet fra driften (TTM)-125.92M
Investeringsudgifter (TTM)6.22M
Fri pengestrøm (TTM)-132.14M
Udbetalt udbytte (TTM)0.00

Finansiel indkomst

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Data om finansiel indkomst
Egenkapitalafkast-94.09%
Afkast af aktiver-65.91%
Afkast af investeret kapital-83.30%
Kontant afkast af investeret kapital-49.51%

INFORMATION OM AKTIER

Aktiediagram

Loading...
Aktiekurs-data
Åbning32.67
Daglig høj32.67
Daglig lav31.04
Daglig volumen284K
Højeste gennem alle tider33.94
1 års analytiker estimat37.33
Beta-
EPS (TTM)-5.07
Udbytte pr. aktie-
Ex-div dato-
Næste dato for resultatpræsentation23 Mar 2023

Nedsidepotensial

Loading...
Nedsidepotensial-data
ACLXS&P500
Nuværende prisfald fra top notering-5.33%-14.21%
Højeste prisfald-62.33%-56.47%
Højeste efterår dato18 May 20229 Mar 2009
Gennemsnitlig fald fra toppen-20.06%-11.49%
Gennemsnitlig tid til nyt højdepunkt17 days13 days
Maks. tid til nyt højdepunkt126 days1805 days
OPLYSNINGER OM VIRKSOMHEDEN
ACLX (Arcellx Inc) company logo
Markedsværdi
1.41B
Markedsværdi kategori
Small-cap
Beskrivelse
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.
Personale
78
Investor relationer
-
SEC-indsendelser
Adm. direktør
Land
USA
By
Aktietype
-
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRÆSENTATIONER
ArrangementerPræsentationer
Loading...
FORSTÅ FORRETNINGEN
Loading...
NYHEDER OM VIRKSOMHEDEN
Alle nyhederPressemeddelelser
Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announ...
2. februar 2023
SANTA MONICA, Calif. & REDWOOD CITY, Calif., January 30, 2023--Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX), today announced the closing of the companies’ previously announc...
30. januar 2023
Gilead Sciences (GILD) gets EMA validation for its application for breast cancer drug Trodelvy in the European Union.
4. januar 2023
Acquisitions news from HZNP and AMGN form the key highlights from the biotech sector during the past week.
14. december 2022
Gilead (GILD) announces deals with Arcellx, Inc. and ImmunoGen to strengthen its oncology pipeline.
12. december 2022
Recent initial public offering Arcellx forged a $325 million cancer deal with Gilead Sciences on Friday, and the IPO stock broke out.
9. december 2022
The deal involves an upfront cash payment of $225 million to Arcellx and a $100 million equity investment from Gilead's Kite Pharma.
9. december 2022
Kite, a Gilead Sciences Inc company (NASDAQ: GILD), announced a global strategic collaboration to co-develop and co-commercialize Arcellx Inc's (NASDAQ: ACLX) lead late-stage product candidate, CART-d...
9. december 2022
Gilead Sciences Inc. said Friday that it will co-develop and co-commercialize Arcellx Inc.'s multiple myeloma treatment candidate, which is currently in Phase 2 clinical trials. Gilead will pay Arcell...
9. december 2022
Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announ...
9. december 2022
Næste side